Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Accounts Payables (2020 - 2025)

Historic Accounts Payables for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $6.5 million.

  • Xeris Biopharma Holdings' Accounts Payables fell 1240.1% to $6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 million, marking a year-over-year decrease of 1240.1%. This contributed to the annual value of $2.3 million for FY2024, which is 8019.89% down from last year.
  • According to the latest figures from Q3 2025, Xeris Biopharma Holdings' Accounts Payables is $6.5 million, which was down 1240.1% from $9.5 million recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Accounts Payables registered a high of $12.1 million during Q3 2023, and its lowest value of $2.3 million during Q4 2024.
  • In the last 5 years, Xeris Biopharma Holdings' Accounts Payables had a median value of $7.1 million in 2024 and averaged $7.7 million.
  • As far as peak fluctuations go, Xeris Biopharma Holdings' Accounts Payables skyrocketed by 20842.7% in 2023, and later tumbled by 8019.89% in 2024.
  • Xeris Biopharma Holdings' Accounts Payables (Quarter) stood at $8.9 million in 2021, then tumbled by 48.39% to $4.6 million in 2022, then skyrocketed by 151.09% to $11.6 million in 2023, then tumbled by 80.2% to $2.3 million in 2024, then surged by 185.02% to $6.5 million in 2025.
  • Its last three reported values are $6.5 million in Q3 2025, $9.5 million for Q2 2025, and $6.4 million during Q1 2025.